Question-and-Answer Session
Operator
Thank you. The call will now be opened for questions. (Operator instructions) Our first question is coming from Ren Benjamin with Rodman. Please go ahead.
Ren Benjamin – Rodman & Renshaw
Hi, good morning and thanks for taking the question.
James Burns
Good morning Ren.
Ren Benjamin – Rodman & Renshaw
I guess just going to the pipeline, can we get an update as to what's happening with each of the trials? So, you reported some good data at ASCO regarding the metastatic breast cancer trials, MKC-1. What's happening with that trial now? Are we following the patients longer? Has it been shut down? When might we see updated data? And then just like that, go down the remaining trials as well.
James Burns
As usual, Ren, I'll turn that question over to Carolyn.
Carolyn Sidor
Good morning. I can certainly address the top line studies. I think it probably goes beyond the call to do a whole roll [ph] call of our entire pipeline, a dozen or so trials. The breast cancer study closed to enrollment and the final data were presented at ASCO, however you are right to point out, we continue to treat patients on that study until they reach one of the predetermined endpoints. The next update you will see on that will be a publication. At this point there is no intent on our part or the investigators’ part to do another presentation at a meeting. And that will provide the updated information on all the remaining patients. As far as other studies where we are looking in Phase II MKC-1 as you know is in a combination study in non-small cell lung cancer with Alimta. That study is reaching the end of its first stage and there will be a determination by the investigators and as to the merits of the data to pursue into the second stage. If it turns out to be positive or negative, we will find some way to get that information out to you. But that should happen shortly.
Ren Benjamin – Rodman & Renshaw
So, I'm sorry to interrupt. That should be a third quarter event?
Carolyn Sidor
Absolutely.
Ren Benjamin – Rodman & Renshaw
Okay.
Carolyn Sidor
The other Phase II study is in second-line pancreatic. Again, that study is designed to go up to 30 plus patients. We always do a look at data since these are all open label studies with the investigators’ somewhere at the halfway mark to make sure that we are still on track to meet our primary endpoint. I intend to do that sometime this fall and we will make those results available to you as well. The other studies are really Phase I in hematological cancer. We are targeting information on that study for ASH this year. Obviously abstracts haven't been submitted yet so we can't say for sure whether ours will be accepted but that's our goal. The other Phase I study is too soon to really speculate on the data for that, which is going on at the University of Wisconsin. The Ovarian/Endometrial study is ongoing in Canada, two parallel groups of patients, clearly the ovarian patient population enrolled more quickly than the endometrial and sometime this third quarter we will be looking at the data for the ovarian arm, although I think it will be certainly fourth quarter into next year before we look at the data from the first stage of the endometrial arm. And again we will find a way to make that known.
- To read the full transcript on Seeking Alpha, click here »
